Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…Abstract Number: 1788 • ACR Convergence 2022
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
Background/Purpose: Hyperuricaemia is common in pulmonary hypertension (PH) occurring in up to 80% of patients with serum uric acid levels(sUA) correlating with poor PH outcomes.…Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…Abstract Number: 1822 • ACR Convergence 2022
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Background/Purpose: ABP-671, a novel selective and potent URAT1 inhibitor reduces reabsorption of uric acid (UA) at the renal proximal tubule, and significantly decreases serum uric…Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…Abstract Number: 0669 • ACR Convergence 2021
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…Abstract Number: 1449 • ACR Convergence 2021
Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
Background/Purpose: Elevated serum urate is the most important risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal…Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…
- 1
- 2
- 3
- …
- 6
- Next Page »